Peter Lynch fit · Growth at a reasonable price (GARP)
Is Esperion Therapeutics, Inc. (ESPR) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
0/100
FNão encaixa
1/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a ESPR
PEG ≤ 1.0
chave—
EPS CAGR ≥ 15%
chave-45.4%
Revenue CAGR ≥ 10%
-12.9%
Net margin > 0
-34.8%
Como ESPR pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$626.17M
P/L (TTM)
-
ROIC (TTM)
26.87%
Margem bruta
53.54%
Perguntas frequentes
What is ESPR's Peter Lynch fit score?
ESPR scores 0/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own ESPR?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ESPR.
How often is this score updated?
ESPR's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende ESPR pessoalmente.